x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230150
| Product Information | |
|---|---|
| CAS No. | 20316-62-5 |
| Formula | C30H26O13 |
| Molecular Weight | 594.52 |
| SMILES | OC1C(O)C(COC(=O)\C=C\C2=CC=C(O)C=C2)OC(OC3=C(OC4=C(C(=CC(=C4)O)O)C3=O)C5=CC=C(O)C=C5)C1O |
| Target | NFkB |
| Product Description | Tiliroside shows a hepatoprotective effect against D-galactosamine (D-GalN)/lipopolysaccharide (LPS)-induced liver injury in mice. Tiliroside enhances fatty acid oxidation via the enhancement adiponectin signaling associated with the activation of both AMP-activated protein kinase and peroxisome proliferator-activated receptor α and ameliorates obesity-induced metabolic disorders. Tiliroside shows very potent anti-complement activity (IC50=5.4 x 10(-5) M) on the classical pathway of the complement system. Tiliroside and gnaphaliin are antioxidants against in vitro Cu 2+ -induced LDL oxidation in the same order of magnitude compared to that of the reference drug, probucol. Tiliroside has anti-diabetic effects, the effects at least partially mediated through inhibitory effects on carbohydrate digestion and glucose uptake in the gastrointestinal tract. Tiliroside has in vivo anti-inflammatory activity, it can inhibit neuroinflammation in BV2 microglia through a mechanism involving TRAF-6-mediated activation of NF-κB and p38 MAPK signalling pathways. |
| Format & Storage | |
|---|---|
| Purity | > 99% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
